U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) – 2024 to 2029

SKU: GMS-3200

Format: PDF

Overall Rating
4.5/5

OVERVIEW

The U.S. insomnia treatment market is expected to cross USD 5.43 billion by 2025, rising from 2020 to 2025 at a CAGR of 3.87%. This rise can be due to the advent of new medications to treat insomnia and government funding to reduce the increasing cost of insomnia. Nonetheless, due to the decline in the sales of branded drugs and the may acceptance of generics due to their low cost and equivalent effectiveness as opposed to branded products, market growth could be hampered.

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 1

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 2

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 3

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 4

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 5

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 6

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 7

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 8

TABLE OF CONTENT

1 U.S. Insomnia Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 U.S. Insomnia Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 U.S. Insomnia Market – Industry Market Entry Scenario
4.1 Regulatory Framework Overview
4.2 New Business and Ease of Doing business index
4.3 Case studies of successful ventures
4.4 Customer Analysis – Top 10 companies

5 U.S. Insomnia Market – Market Forces
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Opportunities
5.2.3 Challenges
5.3 Porters Analysis of Market
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining powers of customers
5.3.3 Threat of new entrants
5.3.4 Rivalry among existing players
5.3.5 Threat of substitutes

6 U.S. Insomnia Market – Strategic Analysis
6.1 Value Chain analysis
6.2 Supplier and distributor analysis (Market share and product dealing strategies)

7 U.S. Insomnia Market – By Treatment (Market Size – & million/billion)
7.1 Pharmacological Treatments
7.2 Non-pharmacological Treatments

8 U.S. Insomnia Market – By Pharmacological Treatment
8.1 Prescription Sleep Aids
8.2 Over-the-Counter Sleep Aids

9 U.S. Insomnia Market – By Non-pharmacological Treatment
9.1 Cognitive Behavioral Therapy for Insomnia (CBTI)
9.2 Hypnotherapy
9.3 Other

10 U.S. Insomnia Market – Entropy
10.1 New product launches
10.2 M&A’s, collaborations, JVs and partnerships

11 U.S. Insomnia Market Company Profile (Key Players)
11.1 Market Share, Company Revenue, Products, M&A, Developments
11.2 Merck & Co., Inc.
11.3 Eisai Co., Ltd.
11.4 Meda Consumer Healthcare, Inc
11.5 Takeda Pharmaceuticals Company Ltd.
11.6 Purdue Pharmaceuticals L.P.
11.7 Sanofi
11.8 Vanda Pharmaceuticals
11.9 Pernix Therapeutics
11.10 Pfizer Inc.
11.11 Company 10
11.12 Company 11 & more

12 U.S. Insomnia Market – Appendix
12.1 Sources
12.2 Abbreviations

Share

Get A Free Sample

Take a look at this complimentary sample which comprises of a variety of market data points such as trend analyses, market estimates, and forecasts. You can explore and evaluate it on your own.

Send me Free Sample

Or View Our License Options:

$3,850.00$5,850.00

Why

Industry Coverage: Global Market Studies has a broad range of industry coverage, spanning various sectors such as healthcare, technology, retail, automotive, and many others. This means that clients can rely on us to provide valuable insights into their respective industries, helping them make informed business decisions.

Our team of experts has years of experience in the market research industry, and they have honed their skills in data analysis, market forecasting, and trend analysis. They are also adept at using advanced research tools and techniques to gather and analyze data, providing clients with accurate and reliable insights.

We understand that each client has unique research needs, and we tailor our research solutions to meet their specific requirements. We work closely with our clients to understand their objectives and provide customized research solutions that address their business challenges.

We are committed to innovation and are constantly exploring new research methods and techniques to provide our clients with cutting-edge insights. This enables us to stay ahead of the curve and deliver the best possible research outcomes.

At Global Market Studies, our clients are at the center of everything we do. We pride ourselves on providing excellent customer service and support, and we are always available to address our clients’ concerns and questions.

83422+ Reports Delivered

Accurate market data is crucial to a successful business strategy. With an 85% + accuracy in all reports, makes us one of the best and most accurate firms in the world.

Need Customized Report ?Call Now

OVERVIEW

The U.S. insomnia treatment market is expected to cross USD 5.43 billion by 2025, rising from 2020 to 2025 at a CAGR of 3.87%. This rise can be due to the advent of new medications to treat insomnia and government funding to reduce the increasing cost of insomnia. Nonetheless, due to the decline in the sales of branded drugs and the may acceptance of generics due to their low cost and equivalent effectiveness as opposed to branded products, market growth could be hampered.

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 9

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 10

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 11

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 12

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 13

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 14

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 15

U.S. Insomnia Market by Non-Pharmacological Therapy (Hypnotherapy, CBTI), Prescription Sleep Aids (Orexin Antagonist, Benzodiazepines, Non-Benzodiazepines) & OTC Treatment (Valerian Root, Antihistamine, Melatonin)) - 2024 to 2029 16

TABLE OF CONTENT

1 U.S. Insomnia Market
1.1 Study Objectives
1.2 Market Definition
1.3 Study Scope
1.3.1 Markets Covered
1.3.2 Geographic Scope

2 RESEARCH METHODOLOGY
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.1.2.3 Breakdown of Primaries
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.3 Market Breakdown and Data Triangulation
2.4 Research Assumptions

3 U.S. Insomnia Market – Executive Summary
3.1 Market Revenue, Market Size and Key Trends by Company
3.2 Key Trends by type of Application
3.3 Key Trends segmented by Geography

4 U.S. Insomnia Market – Industry Market Entry Scenario
4.1 Regulatory Framework Overview
4.2 New Business and Ease of Doing business index
4.3 Case studies of successful ventures
4.4 Customer Analysis – Top 10 companies

5 U.S. Insomnia Market – Market Forces
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.2 Opportunities
5.2.3 Challenges
5.3 Porters Analysis of Market
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining powers of customers
5.3.3 Threat of new entrants
5.3.4 Rivalry among existing players
5.3.5 Threat of substitutes

6 U.S. Insomnia Market – Strategic Analysis
6.1 Value Chain analysis
6.2 Supplier and distributor analysis (Market share and product dealing strategies)

7 U.S. Insomnia Market – By Treatment (Market Size – & million/billion)
7.1 Pharmacological Treatments
7.2 Non-pharmacological Treatments

8 U.S. Insomnia Market – By Pharmacological Treatment
8.1 Prescription Sleep Aids
8.2 Over-the-Counter Sleep Aids

9 U.S. Insomnia Market – By Non-pharmacological Treatment
9.1 Cognitive Behavioral Therapy for Insomnia (CBTI)
9.2 Hypnotherapy
9.3 Other

10 U.S. Insomnia Market – Entropy
10.1 New product launches
10.2 M&A’s, collaborations, JVs and partnerships

11 U.S. Insomnia Market Company Profile (Key Players)
11.1 Market Share, Company Revenue, Products, M&A, Developments
11.2 Merck & Co., Inc.
11.3 Eisai Co., Ltd.
11.4 Meda Consumer Healthcare, Inc
11.5 Takeda Pharmaceuticals Company Ltd.
11.6 Purdue Pharmaceuticals L.P.
11.7 Sanofi
11.8 Vanda Pharmaceuticals
11.9 Pernix Therapeutics
11.10 Pfizer Inc.
11.11 Company 10
11.12 Company 11 & more

12 U.S. Insomnia Market – Appendix
12.1 Sources
12.2 Abbreviations

Download our eBook: Market Mastery

Unleashing revenue potential through strategic market research involves identifying untapped market opportunities, understanding consumer needs and preferences, and developing targeted strategies to capitalize on them. By leveraging data-driven insights, businesses can optimize product offerings, pricing strategies, and marketing efforts to drive revenue growth and stay ahead of competitors.

Related Research Reports